Brief: Oric Says Initial Phase 1 Dose Escalation Data Of Oric-114 In Patients With Egfr And Her2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

ORIC Pharmaceuticals

21/10/2023 17:37

Oct 21 (Reuters) - Oric Pharmaceuticals Inc  ORIC.O :
    * INITIAL PHASE 1 DOSE ESCALATION DATA OF ORIC-114 IN
PATIENTS
WITH EGFR AND HER2 EXON 20 MUTATIONS DEMONSTRATES POTENTIAL
BEST-IN-CLASS PROFILE
    * CNS ACTIVITY OBSERVED AT MULTIPLE DOSE LEVELS
    * SYSTEMIC RESPONSES OBSERVED AT MULTIPLE DOSE LEVELS IN
HEAVILY
PRE-TREATED NSCLC PATIENTS
    * FAVORABLE SAFETY PROFILE WITH MAINLY GRADE 1 AND 2
TREATMENT
RELATED ADVERSE EVENTS
    * MTD NOT REACHED AND DOSE ESCALATION REMAINS ONGOING

Source text for Eikon:  ID:nGNX5tQDGd 
Further company coverage:  ORIC.O 

 ((Reuters.Briefs@thomsonreuters.com;))